Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
14 Nov 2024
// BUSINESSWIRE
31 Oct 2024
// BUSINESSWIRE
Details:
P-317 is an oral BLT1 agonist, small molecule therapy based on Resolvin E1 (RvE1) for the treatment of inflammatory bowel disease (IBD) and cancer.
Lead Product(s): TP-317
Therapeutic Area: Gastroenterology Brand Name: TP-317
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2024
Lead Product(s) : TP-317
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Thetis Reports Positive Initial Phase 1a Results for TP-317 in Healthy Subjects
Details : P-317 is an oral BLT1 agonist, small molecule therapy based on Resolvin E1 (RvE1) for the treatment of inflammatory bowel disease (IBD) and cancer.
Brand Name : TP-317
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 31, 2024
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?